Will Eli Lilly’s Groundbreaking Diabetes Victory Prove Hollow?

The results are in: Eli Lilly's (NYSE: LLY) experimental insulin, peglispro, is superior to Sanofi's (NYSE: SNY) flagship Lantus franchise.

Three late stage studies showed that Lilly's new drug controlled blood sugar and weight gain better than the current market leader. However, despite these tremendous results, Eli Lilly's victory may prove hollow. The specter of liver toxicity may hamper the peglispro's ability to get approved and depress consumer demand if and when it hits the market. 

In this video, Motley Fool health care analyst David Williamson discusses the positive and negatives of Eli Lilly's trial results, why sales could be tough to come by, and when investors can expect further action around this drug.

Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

 


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2956315, ~/Articles/ArticleHandler.aspx, 7/30/2014 6:21:04 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement